



Takeda's Position on Access to Medicines

Summary

- Nearly two billion people across the globe lack access to essential medicines.
- Underserved communities in countries with evolving healthcare systems or limited access to resources are most acutely impacted by barriers to access.
- Takeda is committed to broadening sustainable access to our life-changing medicines and vaccines where there is a high unmet medical need.
- Takeda takes an integrated and sustainable approach, inclusive of public and private partnerships and innovative programming, to broaden patient access and bring better health and brighter futures to patients.

Background

Despite major scientific breakthroughs in recent years, the World Health Organization estimates that globally, nearly 2 billion people lack access to essential medicines. While barriers to access exist around the world, those most acutely impacted are underserved communities in countries with evolving healthcare systems or limited access to resources. Barriers to access within, and between, populations range from the levels of capacity and resources needed to prevent, educate, and raise awareness within a community, to the specialized skills needed by healthcare to screen, diagnose and treat patients.

Takeda's Perspective

As a patient-focused, R&D-driven, global biopharmaceutical company, Takeda exists to bring better health and a brighter future to patients around the world. Guided by values of Takeda-ism and

brought to life through our decision-making framework of Patient-Trust-Reputation-Business, in that order, our Access to Medicines approach is central to our commitment to patients and is outlined in our corporate philosophy.

Takeda is committed to broadening sustainable access to our life-changing medicines and vaccines where there is a high unmet medical need – particularly for patients in underserved communities. Takeda’s approach to broadening sustainable access for patients is guided by three core pillars: integration, sustainability and collaboration.

Takeda’s Approach

- **Integration:** Takeda’s Access to Medicines approach is a cross-functional effort, integrated within our business strategy and across our operations to prioritize access from start to finish of a medicine’s development and delivery process. By embedding access commitments into our business strategy, from research & development to commercialization, we are actively addressing the barriers to access for patients to our life-changing medicines and vaccines.
- **Sustainability:** At Takeda we believe that to meet the long-term needs of patients, access frameworks must be sustainable. We also recognize different contexts and barriers mean imposing a ‘one-size-fits-all’ approach is often ineffective. Our approach to delivering sustainable access to medicines initiatives includes:
 - Ensuring uninterrupted, sufficient, and timely supply of products.
 - Addressing healthcare infrastructure and capacity across the entire patient experience, from disease awareness, to diagnosis and management, to ongoing patient care and support.
 - Understanding treatment duration – taking into consideration the length of time a patient requires access to treatment, the resources required to deliver treatment for the appropriate duration and ongoing access to healthcare professional support.
 - Establishing safety and efficacy data to support use.
 - Following pro-access IP arrangements and where possible, supporting voluntary licenses or offering licenses for low-cost access to our medicines – please see [here](#) for our full position on IP and [here](#) for pricing.
 - Delivering targeted, sustainable, and locally specific initiatives, while remaining steadfast in our commitment to prioritize unmet patient needs through uninterrupted access to medicines and our world-class research and development (R&D) efforts, transformative therapies and a values-based approach to strengthening health care systems.

- **Collaboration:** Takeda believes that mobilizing collective efforts across the public and private sector is critical to address the underlying barriers to access and strengthen in-country health systems, allowing for the sustainable and scalable implementation of access programs. This includes partnering with policymakers, governments, NGOs, industry peers, healthcare professionals, patient organizations and civil society, to support the sustainability of healthcare systems. Broadening access to medicines and vaccines is not something we can do alone. By partnering with diverse stakeholders, we are actively addressing barriers to access and strengthening health systems to improve lives worldwide.

Takeda's Value-Based Strategic Imperatives

In order to achieve our vision of bringing better health and a brighter future to patients in a sustainable way, we focus our efforts on the following strategic imperatives:

- Collaborate with partners to broaden patient access by strengthening healthcare systems
- Introduce and support innovative programs that address affordability barriers and enable access to medicines and vaccines, including:
 - Tiered pricing
 - Takeda's means-tested innovative Patient Assistance Programs
 - Value Based Healthcare models
- Work with policy makers to broaden patient access to our medicines and vaccines

Conclusion

Our commitment to broadening patient access to our life-changing medicines and vaccines in underserved communities is ingrained in our corporate values, is integrated into our business model, and is improving lives worldwide by working with others to create and broaden sustainable access to medicines and vaccines.

About Takeda Pharmaceutical Company Limited

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas:

Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. www.takeda.com

March, 2022